Yazar "Eskazan, Ahmet Emre" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting
    (Taylor & Francis Ltd, 2022) Eskazan, Ahmet Emre; Ali, Ridvan; Alnigenis, Ebru; Ayyildiz, Orhan; Haznedaroglu, Ibrahim; Kirkizlar, Onur; Kurtoglu, Erdal
    Introduction The therapeutic landscape of chronic myeloid leukemia (CML) has evolved significantly since the introduction of imatinib. The European LeukemiaNet (ELN) recommendations serve as a guide for diagnosis, treatment, and monitorization of CML, but availability and accessibility of diagnostic tools and medications affect their applicability. Areas covered This article provides an overview of the current clinical management of CML in Turkey with reference to the key outputs of the online expert meeting held in November 2020. The applicability of the ELN 2020 recommendations for treating CML in clinical practice was also discussed. Expert opinion Imatinib is the only reimbursed and the most preferred first-line treatment in CML restricting the upfront use of second-generation tyrosine kinase inhibitors (TKIs), thereby limiting the applicability of treatment-free remission approach in Turkey. The ELN recommendations about using the EUTOS Long-Term Survival (ELTS) score for risk assessment and focusing on patient reported outcomes and quality of life can be enhanced with educational activities. The widespread availability of standardized technical infrastructure for diagnosing and monitoring CML will contribute to better disease management. Establishing a sustainable national database for CML is valuable for observing patient characteristics and disease outcomes as well as the impact of treatment patterns over time.
  • Küçük Resim Yok
    Öğe
    Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients
    (Galenos Yayincilik, 2013) Sahin, Fahri; Saydam, Güray; Comert, Melda; Uz, Burak; Yavuz, Akif Selim; Turan, Esra; Yonal, Ipek; Atay, Hilmi; Keltikli, Engin; Turgut, Mehmet; Pehlivan, Mustafa; Akay, Meltem Olga; Gurkan, Emel; Paydas, Semra; Kahraman, Selda; Demirkan, Fatih; Kirkizlar, Onur; Akpinar, Seval; Pamuk, Gulsum Emel; Demir, Muzaffer; Ozbas, Hasan Mucahit; Sonmez, Mehmet; Gulturk, Mine; Salihoglu, Ayse; Eskazan, Ahmet Emre; Ar, Cem; Sahin, Handan Haydaroglu; Ongoren, Seniz; Baslar, Zafer; Aydin, Yildiz; Yenere, Mustafa Nuri; Tuzuner, Nukhet; Ferhanoglu, Burhan; Haznedaroglu, Ibrahim C.; Ilhan, Osman; Soysal, Teoman
    Objective: here have been tremendous changes in treatment and follow-up of patients with chronic myeloid leukemia (CML) in the last decade. Especially, regular publication and updating of NCCN and ELN guidelines have provided enermous rationale and base for close monitorization of patients with CML. But, it is stil needed to have registry results retrospectively to evaluate daily CML practices. Materials and Methods: In this article, we have evaluated 1133 patients' results with CML in terms of demographical features, disease status, response, resistance and use of second-generation TKIs. Results: The response rate has been found relatively high in comparison with previously published articles, and we detected that there was a lack of appropriate and adequate molecular response assessment. Conclusion: We concluded that we need to improve registry systems and increase the availability of molecular response assessment to provide high-quality patient care.